RT Journal Article
SR Electronic
T1 Integrative approach identifies <em>SLC6A20</em> and <em>CXCR6</em> as putative causal genes for the COVID-19 GWAS signal in the 3p21.31 locus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.09.21255184
DO 10.1101/2021.04.09.21255184
A1 Silva Kasela
A1 Zharko Daniloski
A1 Tristan X. Jordan
A1 Benjamin R. tenOever
A1 Neville E. Sanjana
A1 Tuuli Lappalainen
YR 2021
UL http://medrxiv.org/content/early/2021/04/13/2021.04.09.21255184.abstract
AB To date the locus with the most robust human genetic association to COVID-19 susceptibility is 3p21.31. Here, we integrate genome-scale CRISPR loss-of-function screens and eQTLs in diverse cell types and tissues to pinpoint genes underlying COVID-19 risk. Our findings identify SLC6A20 and CXCR6 as putative causal genes that mediate COVID-19 risk and highlight the usefulness of this integrative approach to bridge the divide between correlational and causal studies of human biology.Competing Interest StatementN.E.S. is an advisor to Vertex. T.L. advises and has equity in Variant Bio, and is a member of the scientific advisory board of Goldfinch Bio. The remaining authors declare that they have no competing interests.Funding StatementS.K. and T.L. are supported by NIH/NHLBI (R01HL142028). Z.D. is supported by an American Heart Association postdoctoral fellowship (grant no. 20POST35220040). Postdoctoral fellowship support for T.X.J. is provided by the NIH (grant no. R01AI123155). B.R.t. is supported by the Marc Haas Foundation, the National Institutes of Health, and DARPA's PREPARE Program (HR0011-20-2-0040). N.E.S. is supported by NYU and NYGC startup funds, NIH/NHGRI (DP2HG010099), NIH/NCI (R01CA218668), DARPA (D18AP00053), the Sidney Kimmel Foundation, and the Brain and Behavior Foundation. T.L. is supported by NIH/NIMH (R01MH106842) and NIH/NHGRI (UM1HG008901).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable - we are analyzing already published dataAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analyzed during the current study are available from the following repositories: CRISPR screen data can be accessed from GEO repository under an accession number GSE158298, summary statistics of the COVID-19 GWAS (release 3) from the COVID-19 Human Genetics Initiative webpage, eQTL summary statistics can be downloaded from the eQTL Catalogue and the GTEx Portal. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158298 https://www.covid19hg.org/results/r3/ https://www.ebi.ac.uk/eqtl/ https://gtexportal.org/